Evidence map›Paper›PMID 41152539›Full record

ArticleJournal of neurology2025

Complete Epstein-Barr virus seropositivity in a cohort of pediatric onset multiple sclerosis: a comparison to other autoimmune diseases.

Gabriele Monte, Giuseppe Tiralongo, Laura Papetti, Michela Ada Noris Ferilli, Martina Proietti Checchi, Alessandra Voci, Claudia Ruscitto, Marco Salvetti, Gianmarco Bellucci, Massimiliano Valeriani

Abstract readComparative Study
PubMed Publisher
In one paragraph

Article in Journal of neurology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Gabriele Monte *Developmental Neurology Unit, Bambino Gesù Children's Hospital, IRCCS, 00165, Rome, Italy. gabriele.monte@opbg.net.ORCID http://orcid.org/0000-0002-4763-7784
Giuseppe Tiralongo *Academy of Pediatrics, Tor Vergata University of Rome, Rome, Italy.
Laura PapettiDevelopmental Neurology Unit, Bambino Gesù Children's Hospital, IRCCS, 00165, Rome, Italy.
Michela Ada Noris FerilliDevelopmental Neurology Unit, Bambino Gesù Children's Hospital, IRCCS, 00165, Rome, Italy.
Martina Proietti ChecchiDevelopmental Neurology Unit, Bambino Gesù Children's Hospital, IRCCS, 00165, Rome, Italy.
Alessandra VociDevelopmental Neurology Unit, Bambino Gesù Children's Hospital, IRCCS, 00165, Rome, Italy.
Claudia RuscittoDevelopmental Neurology Unit, Bambino Gesù Children's Hospital, IRCCS, 00165, Rome, Italy.
Marco SalvettiCentre for Experimental Neurological Therapies, Department of Neurosciences, Mental Health and Sensory Organs, Sapienza University, 00189, Rome, Italy.
Gianmarco Bellucci *Centre for Experimental Neurological Therapies, Department of Neurosciences, Mental Health and Sensory Organs, Sapienza University, 00189, Rome, Italy.
Massimiliano Valeriani *Developmental Neurology Unit, Bambino Gesù Children's Hospital, IRCCS, 00165, Rome, Italy.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionThe role of Epstein-Barr virus (EBV) in multiple sclerosis (MS) pathogenesis is supported by the increased MS risk after infectious mononucleosis. This study aimed to evaluate EBV infection in our pediatric-onset MS (POMS) cohort.

methodsMS patients with disease onset < 18 years of age seen at Bambino Gesù Children's Hospital were included. We searched for anti-EBV nuclear antigen (EBNA) Immunoglobulin G (IgG) and anti-viral capsid antigen (VCA) IgG and IgM. For comparison, we analyzed the EBV infection seroprevalence in an age- and sex-matched control cohorts of immunologically-healthy children and subjects with non-neurological autoimmune diseases.

resultsFifty-seven POMS were included; all had a previous EBV infection. The controls' cohort included one-hundred and sixty-two patients with a median age of 12 years (range 6-17), encompassing two subgroups: non-autoimmune (i.e. primary headaches) and autoimmune controls, namely inflammatory bowel disease and juvenile idiopathic arthritis. In the control group, ninety-six (59%) were EBV seropositive. EBV seropositivity was significantly higher in POMS than in the controls' cohort (OR = 79.2, 95% C.I. 4.8-1305), and compared to autoimmune and non-autoimmune controls separately (p < 0.0001). DISCUSSION: In our POMS cohort, EBV seropositivity was 100%, higher than previously reported. Our results support a disease-specific role of EBV in the MS development compared to other pediatric autoimmune disorders, consistent with evidence reported in adult-onset MS.

Indexed as

Autoimmune DiseasesEpstein-Barr Virus InfectionsHerpesvirus 4, HumanMultiple SclerosisAdolescentAntibodies, ViralChildCohort StudiesEpstein-Barr Virus Nuclear AntigensFemaleHumansImmunoglobulin GMaleSeroepidemiologic StudiesAntibodies, ViralEpstein-Barr Virus Nuclear AntigensImmunoglobulin GEpstein-Barr virusMononucleosisPediatric-onset multiple sclerosis

Identifiers

PMID41152539

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.